CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already ...
Phase 3
Nashville, Tennessee, United States and 18 other locations
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Nashville, Tennessee, United States and 125 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
Nashville, Tennessee, United States and 46 other locations
Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.
Phase 1
Nashville, Tennessee, United States and 5 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Nashville, Tennessee, United States and 92 other locations
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian...
Phase 2
Nashville, Tennessee, United States and 19 other locations
phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian...
Phase 1
Nashville, Tennessee, United States and 8 other locations
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and phar...
Phase 1
Nashville, Tennessee, United States and 23 other locations
of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study will ...
Phase 1, Phase 2
Nashville, Tennessee, United States and 52 other locations
Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...
Phase 3
Nashville, Tennessee, United States and 179 other locations
Clinical trials
Research sites
Resources
Legal